Title of article :
Skeletal safety of tiludronate
Author/Authors :
R. M. Neer، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 1995
Pages :
3
From page :
501
To page :
503
Abstract :
The medical uses of bisphosphonates derive from their exceptional ability to inhibit bone resorption. However, bone resorption is essential for the healing of fractures, the repair of microscopic fatigue cracks in bone, and the internal reorientation of trabecular and cortical bone in response to altered mechanical strains. In theory, overdose with bisphosphonates might interfere with the repair of fractures or weaken bone strength (by forcing bones to accumulate and propagate fatigue cracks or by abolishing the skeletonʹs adaptive powers). Regulatory agencies (particularly in the USA) have, therefore, set comprehensive and stringent safety criteria before the marketing of bisphosphonates can be approved. Some bisphosphonates can also inhibit bone mineralization, alter hepatic function, or cause gastritis/ esophagitis. The safety profile of tiludronate will be described from this perspective, emphasizing the results of prolonged treatment in animals, and studies in humans.
Keywords :
Tiludronate , Resorption , fractures , Pagetיs disease , Cortical , mineralization , Trabecular
Journal title :
Bone
Serial Year :
1995
Journal title :
Bone
Record number :
489952
Link To Document :
بازگشت